Infliximab is an appropriate second‐line therapy in infants with steroid refractory pyoderma gangrenosum. (27th January 2022) - Lesmeister, L.M.; Peitz, J.; von Kleist‐Retzow, J.C.; Lee‐Kirsch, M.A.; Torrelo, A.; Tantcheva‐Poor, I.; Broekaert, I.J.